OTCMKTS:MYLGF - Mirati Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous Close$6.07
Today's RangeN/A
52-Week RangeN/A
Average Volume355 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
MethylGene, Inc. operates as a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics for cancer and infectious disease.

Receive MYLGF News and Ratings via Email

Sign-up to receive the latest news and ratings for MYLGF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry N/A
Previous Symbol


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding SharesN/A
Market Cap$0.00
OptionableNot Optionable

Mirati Therapeutics (OTCMKTS:MYLGF) Frequently Asked Questions

What is Mirati Therapeutics' stock symbol?

Mirati Therapeutics trades on the OTCMKTS under the ticker symbol "MYLGF."

Has Mirati Therapeutics been receiving favorable news coverage?

News articles about MYLGF stock have been trending neutral this week, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Mirati Therapeutics earned a daily sentiment score of 0.4 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 3.0 out of 10, indicating that recent news coverage is unlikely to have an effect on the company's share price in the near term.

Who are Mirati Therapeutics' key executives?

Mirati Therapeutics' management team includes the folowing people:
  • Martin Godbout Ph.D, Chairman of the Board (Age 57)
  • Charles M. Baum M.D., Ph.D., President, Chief Executive Officer, Director (Age 55)
  • Mark J. Gergen, Chief Operations Officer, Executive Vice President (Age 51)
  • Rachel W. Humphrey M.D., Chief Medical Officer, Executive Vice President (Age 51)
  • Jamie A. Donadio, Vice President - Finance (Age 38)
  • Henry J. Fuchs M.D., Ph.D., Independent Director (Age 55)
  • Rodney W. Lappe Ph.D., Independent Director (Age 58)
  • Peter A. Thompson M.D., Independent Director (Age 53)

How do I buy shares of Mirati Therapeutics?

Shares of MYLGF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

MarketBeat Community Rating for Mirati Therapeutics (OTCMKTS MYLGF)

Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  124 (Vote Outperform)
Underperform Votes:  49 (Vote Underperform)
Total Votes:  173
MarketBeat's community ratings are surveys of what our community members think about Mirati Therapeutics and other stocks. Vote "Outperform" if you believe MYLGF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYLGF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/19/2018 by MarketBeat.com Staff

Featured Article: What is the yield curve?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel